Autres langues Senti Biosciences, Inc.

Actions

SNTI

US81726A1007

Cours en clôture Nasdaq Autres places de cotation 00:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
0,38 ^USD	+5,56%		+35,28%	-42,42%

30/04	Senti Biosciences, Inc. annonce la publication des données précliniques de SENTI-202 qui démontrent le potentiel de la thérapie cellulaire CAR-NK pour le traitement de la leucémie myéloïde aiguë (LMA).	CI
26/04	Senti Biosciences, Inc. annonce la démission de Deborah Knobelman en tant que trésorière et responsable du développement de l'entreprise, à compter du 3 mai 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	30/04
Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	30/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13/11
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	06/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Senti Biosciences, Inc.

Actions

SNTI

US81726A1007

Autres langues

Filtres